Soleno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing treatments for rare diseases. Its flagship project involves Diazoxide Choline Extended-Release tablets, aimed at treating Prader-Willi Syndrome, currently in Phase III trials. Originating in 1999 and initially known as Capnia, Inc., the company rebranded to its current name in 2017 and operates from Redwood City, California.
One of the stocks to benefit the most from the artificial intelligence (AI) craze has been Super Micro Computer (Nasdaq: SMCI | SMCI Price Prediction). Before AI took over, Super Micro flew…
Soleno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing treatments for rare diseases. Its flagship project involves Diazoxide Choline Extended-Release tablets, aimed at treating Prader-Willi Syndrome, currently in Phase III trials.
